Company intelligence / Profile preview

Beta Pharma (Shanghai)

Shanghai, Shanghai Shi, Chinabetapharma.cn ↗

Ownership: Private
Development stage: Other

Overview

Lead drug BPI-1178 (CDK4/6 inhibitor) is in Phase 1/2 for advanced malignant solid neoplasms. Rezivertinib (third-generation EGFR TKI for EGFR T790M) is in Phase 1 for metastatic NSCLC. Several anti-PDL1 antibody and ADC assets in preclinical/early phase. At least one product (icotinib, not developed in Shanghai entity) is approved in China.

Therapeutic areas: Oncology
Modalities: Small moleculeAntibodyAntibody-drug conjugateSynthetic peptide
Industry: Biotech

Partnerships

WuXi STA (process R&D and manufacturing partnership)[4]

Beyond the preview

Go deeper on Beta Pharma (Shanghai).

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta Pharma (Shanghai).

Explore the full profile